38 results about "Oncology drugs" patented technology

This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations which comprise a polar aprotic solvent, preferably dimethyl acetamide (DMA). Formulations comprising these solvent provide therapeutically effective treatments of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.

The present invention relates to methods of passive infrared imaging and dynamic infrared imaging of a tumor or lesion (“DIR”) where multiple images are taken before, during and after heating or cooling the tumor or lesion. Patterns of intensity of infrared emission in the infrared image(s) are related to the level of vascularity or metabolic activity of the tumor or lesion, and are used to identify size and shape of the tumor or lesion. The patterns can also be used to determine whether Kaposi's sarcoma lesions, skin cancer lesions and melanomas are active or inactive. Changes in the patterns of infrared emission determined by comparing images taken before, during and after the onset of drug or radiation therapy, are used to assess efficacy of the therapy. The methods can also be used to study tissue affected by angiogenic diseases.

The present invention provides a method of inhibiting the growth of or promoting differentiation and destruction of cancer stem cells (CSCs) comprising contacting the cancer stem cells with a compound having the structure:or a pharmaceutically acceptable salt thereof.

The present invention belongs to the technical field of medicine and biology, and relates to an antitumor drug synergism drug, particularly to a tumor treatment synergism drug composition comprising an autophagy inhibitor and adriamycin. The combination drug comprises one or a plurality of autophagy inhibitors and adriamycin, and is provided for treating tumors by adopting a combination administration or sequential use mode, wherein tumor cell autophagy induced by adriamycin can be inhibited to counteract antagonism effects of tumors on treatments of adriamycin due to autophagy so as to significantly enhance tumor treatment effects of adriamycin. The synergism drug composition is suitable for treatment of lymphoma, lung cancers, brain tumors, breast cancers and myeloma.

The invention discloses application of an iridium complex in preparing mitochondria targeted anti-tumor drugs. The structural formula of the iridium complex is [Ir(ppy)2(HPIP)]C1, wherein ligand represented by ppy is 2-phenylpyridine, ligand represented by HPIP is 3-(1H-imidazole[4,5-f][1,10]phenanthroline-2-yl)phenol. The iridium complex has the high inhibiting effect on human tumor cells HeLa, HepG2, A-549 and a cisplatin resistant strain CP / R-A549, mitochondria in tumor cells can be stored up, tumor cell apoptosiss can be induced, and the iridium complex can serve as the new anti-tumor drugtaking tumor cell mitochondria as target sites.

The invention discloses a use of a bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors. Anti-cancer experiments of human tongue squamous cancer cells are carried out in vitro through a bufadienolide extract and monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, cinobufagin, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, and experimental results show that the bufadienolide compound has strong inhibition effect on tongue squamous cancer cells and compared with the bufadienolide extract and eight monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, cinobufagin has a stronger anti-tumor cell activity. The bufadienolide compound provided by the invention has clear components, controllable quality, strong anti-tumor activity and little adverse reaction and is expected to be developed into a novel anti oral mucosal malignant tumor medicine.

The invention belongs to the technical field of oncology, and discloses a medicine mixing device for the oncology department. The medicine mixing device comprises a box body; a medicine feeding hopper is arranged on the box body; a crushing cylinder is arranged at the lower end of the medicine feeding hopper; a sun gear is arranged in the crushing cylinder; a planetary gear is arranged on the sun gear; a driving rod is arranged on the sun gear; a driven rod is arranged on the planetary gear; a crushing box is arranged on one side of the crushing cylinder; a motor is arranged in the crushing box and is connected with the driving rod; an opening is formed in the lower end of the crushing cylinder; a medicine storage box is arranged at the lower end of the opening; a fixing strip is arranged at the lower end of the medicine storage box; a connecting plate is arranged at the lower end of the fixing strip; a grinding wheel is arranged at the bottom end of the connecting plate; a limiting block is arranged in the box body; a limiting groove is formed in the limiting block; a grinding seat is arranged in the limiting groove; a driving rod is arranged on the grinding base; first transmission teeth are arranged on the driving rod; second transmission teeth are arranged on the first motor; and a grinding groove is formed in the grinding base. The medicine mixing device solves the problem that granular medicine cannot be smashed and ground in the prior art, and is suitable for mixing and grinding oncology medicine.

The invention belongs to the technical field of medical devices, and discloses a medical oncology drug delivery device and method, including a handle, a switch, a connecting rod, a transparent cover plate, a drug injection tube, a medicine mix cavity, a sleeve rod, a spring, a micro-photographic head, a medicine feeding pinhole, a micro motor, a chain, a barrier plate, a flat-head bent rod, a lighting lamp, a liquid level detection module, a wireless communication module, a smartphone, a housing and a tumor prediction module. A liquid level detection module detect that data information of theliquid level in the drug mixing cavity in time, and supply the drug liquid to the drug mixing cavity in time. The algorithm of wireless communication module can obtain better capacity performance, andthe difference between the algorithm and the optimal antenna selection algorithm is not very big, which not only maintains the diversity effect of wireless communication system, but also reduces thecomplexity of system coding. In addition, through the tumor prediction module to establish a tumor prediction model, can be more accurate in tumor prediction, to meet the needs of users.

The invention discloses a novel medical-oncology drug-interventional therapy apparatus which comprises a bottom plate. A medical kit and a waste-liquid box are fixed on the left side of the upper surface of the bottom plate, the medical kit is located on the front side of the waste-liquid box, a heating unit, a temperature sensor and a second liquid level sensor are sequentially fixed in the bottom surface of the medical kit from left to right, a first liquid level sensor is fixed in the bottom surface of the waste-liquid box, a first liquid pump and a second liquid pump are fixed in the middle of the upper surface of the bottom plate, a drug inlet of the first liquid pump is communicated with a liquid outlet of the medical kit through a guide pipe, a liquid outlet of the first liquid pump is communicated with a liquid inlet of a first intervention needle through a guide pipe, ultrasonic wave generated from an ultrasonic transducer promotes absorption of liquid in sicken position of a tumor patient, and therapy effect is improved. The novel medical-oncology drug-interventional therapy apparatus is complete in function and convenient in use, the apparatus is flexible in operation and convenient in use when medical-oncology drug-interventional therapy is performed, and burden of medical personnel is alleviated.

The invention belongs to the field of antitumor drugs and specifically discloses application of aspirin in preparing medicine for treating NSCLC (non-small cell lung cancer). In comparison with the fact that osimertinib is applied alone to treat EGFR(+) NSCLC, the drug combination of the aspirin and the osimertinib can effectively inhibit proliferation of the EGFR(+) NSCLC cells, so as to promoteapoptosis of the EGFR(+) NSCLC cells. The drug combination of the aspirin and the osimertinib enhances sensitivity of the NSCLC patient to EGFR-TKI, overcomes the defect of highly possible drug resistance to the osimertinib, increases the effective treatment time of the osimertinib and can further improve the prognosis of the EGFR(+) NSCLC patient.

The present invention discloses application of Etonogestrel in the preparation of anti-prostate cancer products. The present invention discloses application of Etonogestrel in the preparation of anti-prostate cancer products. Experiments in the present invention conduct relocation on anti-tumor medicament Etonogestrel approved by FDA and CFDA; according to the different tumor cell lines (tissue types) and mutation sites, drugs with non-anti-tumor indications are screened, and the invention discovers the novel anti-prostate cancer application of Etonogestrel, so as to realize novel application of old medicament.

The present invention discloses a class of deuterated 3-(4,5-substituted amino pyrimidine)phenyl derivatives, and applications thereof, wherein the deuterated 3-(4,5-substituted amino pyrimidine)phenyl derivatives are compounds having a structure represented by a formula (I) or pharmaceutically acceptable salts thereof, and the compounds or the salts thereof can be used for the treatment or prevention of diseases or conditions through epidermal growth factors with mutated forms, can effectively inhibit the growths of a variety of tumor cells, can inhibit other proteases of EGFR and Her family,and can be used for preparing antitumor drugs. The formula (I) is defined in the specification.

The invention provides application of fulvestrant in preparing an antimicrotubular chemotherapeutic drug resistance reversal agent. The fulvestrant reverts antimicrotubular chemotherapeutic drug resistance of breast cancer cells without relying whether estrogen receptors are expressed or not and also without relying whether the function of restricting P-glycoprotein is achieved or not. The fulvestrant and the antitumor drugs which are used together can accelerate the antitumor drugs to induce apoptosis of drug-resistance cells of breast cancer with negative estrogen receptors. The fulvestrant has been approved to be used for clinics and has the advantages of less side effects, good tolerance of a patient, less cross drug resistance with other estrogen receptor regulators or chemotherapeutic drugs, and the like, has clinical operability while being collaboratively used with common chemotherapeutic drugs for clinically treating the breast cancer, such as taxol, adriamycin, vinorelbine, and the like and has favorable clinical application prospect as the antimicrotubular chemotherapeutic drug resistance reversal agent for treating the drug-resistance breast cancer.

The invention discloses a screening model of drugs against head and neck cancer tumors. The screening model is constructed through the specific steps that (1) the surface of a hollow fiber reactor istransformed through acetic acid plasma, and sterilization treatment is conducted; (2) head and neck cancer tumor single cells are separated; (3) the head and neck cancer tumor single cells are plantedinto the hollow fiber reactor for cell adhesion culture; (4) a target drug is determined, a healthy mouse serves as a drug delivery target, the hollow fiber reactor is taken and planted into the backof the mouse, and a mouse head and neck cancer tumor pathological model is established after 24 h; and (5) the target drug is applied to the mouse head and neck cancer tumor pathological model, the drug is delivered once every two days, and the screening model of the drugs against the head and neck cancer tumors is constructed. According to the screening model, efficacy evaluation of the drugs against the head and neck cancer tumors can be quickly conducted, the time required by a pharmacological experiment of a traditional mouse xenograft model is greatly shortened, the time required from the experiment to the result does not exceed 20 days, the clinical experiment cost can be lowered, and the screening model is easy to popularize.

The invention discloses a polypeptide, an anti-tumor drug made from the polypeptide and a preparation method of the anti-tumor drug. The structural formula of the polypeptide is Ac-IIIIIIKKKKK-NH2. The anti-tumor drug includes a polypeptide nano drug carrier which is a nanosphere structure that can be broken in an acid environment, and a liposoluble drug is embedded into the polypeptide nano drug carrier. The preparation method of the anti-tumor drug includes the following steps that S1, the liposoluble drug and the polypeptide are dissolved in a DMSO; S2, a PBS buffer solution is added into the DMSO for ultrasonic mixing; S3, mixed liquid is added into dialysis bags for dialysis for 24 hours to remove the DMSO and unbound liposoluble drugs, and the prepared anti-tumor drug is obtained.

This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.

The invention relates to the technical field of medicine smashing, in particular to an oncology medicine smashing device based on high-frequency vibration. The oncology medicine smashing device based on high-frequency vibration comprises a vibration smashing structure and a rotary grinding structure located below the vibration smashing structure; the vibration smashing structure comprises a bottom plate, a shell is fixed to the bottom plate, a through hole is formed in the bottom plate, a second supporting rod is arranged below the bottom plate, a rotating disc is connected to the other side of a connecting shaft, the connecting shaft is eccentrically arranged on the rotating disc, a connecting plate is arranged below the rotating disc, the upper surface of the connecting plate is in contact with the surface of the rotating disc, a connecting rod is arranged below the connecting plate, penetrates through the through hole and is sleeved with a spring, the spring is located between the connecting plate and the bottom plate, a medicine pounding pestle is connected below the connecting rod, the bottom of the medicine pounding pestle is of a spherical structure, a medicine pounding groove is formed below the medicine pounding pestle, the shape and size of the medicine pounding groove are matched with the shape and size of the medicine pounding pestle, and a supporting plate is arranged on the outer side of the medicine pounding groove. The problem that a common smashing machine cannot evenly smash traditional Chinese medicine during smashing is solved.

The invention provides an oncology drug processing device, which relates to the field of oncology. The oncology drug treatment device includes a motor and two brackets, a treatment box is arranged above the two brackets, the motor is fixedly connected to the right side of the treatment box, the treatment box is fixedly connected to the two brackets, and the inside of the treatment box is provided with Two grinding wheels, the left and right sides of the two grinding wheels are fixedly connected with four grinding plates, the four grinding plates located on the right side of the right grinding wheel are all clamped with fine grinding plates on the outside, and the inside of the processing box is inserted A rotating shaft is connected, the grinding wheel on the right is fixedly sleeved on the outside of the rotating shaft, the grinding wheel on the left is movably sleeved on the outside of the rotating shaft, and a control panel is arranged on the left side of the processing box. The oncology drug processing device achieves the effect of fully processing drugs by setting a motor, a rotating shaft, two grinding wheels and a grinding box, and solves the problem that the processing device in the prior art is not sufficiently ground and the time required for sufficient grinding longer.

The invention relates to the technical field of medical devices, and discloses a medical oncology drug delivery device, comprising a first drug delivery box and a second drug delivery box. A knob is arranged on the left side of the medicine feeding tube, the knob is sleeved on the outer wall of the left end of the rotating shaft, the right side of the knob is in contact with the left side of the sealing ring, and the right side of the sealing ring is in contact with the left side of the medicine feeding tube. contact, the sealing ring is sleeved on the outer wall of the rotating shaft, the right end of the rotating shaft runs through the left side of the medicine inlet tube and the left side of the closing plate in turn and extends to the right side of the medicine inlet tube, and the upper part of the first medicine box is provided There is a first drive motor. By pulling the two pull rings relative to each other, the two blocks can be moved relative to each other, and the two connecting blocks can also be moved relative to each other until the two blocks are disengaged from the bayonet, and then move the stirring blade to the left, and finally the disassembly can be completed, which is convenient Clean the stirring blades.

Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.

The invention discloses a screening system and method for medical oncology treatment drugs. The method comprises the steps: acquiring the basic information of a first user; extracting gender information and age information of the first user from the basic information of the first user; acquiring a first feature vector of the first user; acquiring a first special label of the first user; acquiring a first screening condition according to the first feature vector and the first special label; extracting illness state information of the first user from the basic information of the first user; acquiring a second screening condition of the first user according to the illness state information of the first user; and inputting the first screening condition and the second screening condition into a medical oncology drug screening model to obtain a first drug screening result. The invention solves the technical problems that: in the prior art, due to the fact that the drug resistance of patients is different, suitable and efficient drugs cannot be dispensed accurately according to the specific conditions of the patients.

The invention discloses a drug delivery device for medical oncology, which comprises a needle body, the inner side wall of the needle body is fixedly connected with a syringe, the inner side wall of the syringe is sealed and slidably connected with a piston, and the top of the piston is fixedly connected with a Push rod, the outer wall of the needle body is fixedly connected with a positioning block, the outer wall of the needle body is fixedly connected with a liquid medicine tank, the bottom of the liquid medicine tank is fixedly connected with a positioning seat, and the inner side of the liquid medicine tank is fixedly connected with a positioning block. The wall is sealed and slidably connected with a slide plate, and the top of the slide plate is connected with a dosing tube through a sealed slide connection. The present invention realizes the repeated absorption of the liquid medicine in the syringe through the pressure difference, which improves the injection efficiency of the diseased part of the patient and greatly improves the Reduce the pain of the patient, save the time of the medical staff, better ensure the stability of the connector by fixing and sealing the joint, and prevent the loss of the connector and the extravasation of the drug solution from causing damage to the patient's skin. damage, protecting the safety of the patient and improving the stability of the device.

The invention provides a recombinant plasmid containing WSB1 gene promoter and reporter gene, its construction method and application. Specifically, the WSB1 gene promoter-specific sequence was cloned, recombined into the vector sequence containing the firefly luciferase reporter gene, and a recombinant plasmid containing the WSB1 gene promoter and reporter gene was constructed, and then the constructed recombinant plasmid was combined with Renilla luciferase The reporter gene plasmid pRL-TK was co-transfected into tumor cells to make it stably expressed. Finally, the activity of WSB1 gene promoter to initiate transcription was reflected by detecting the activity of dual luciferase, so as to be applied to targeted screening of anti-tumor drugs. The recombinant plasmid constructed by the present invention adopts the WSB1 gene promoter, and selects a specific promoter sequence. The drug screening model constructed has high specificity, high sensitivity and high accuracy, and realizes the antibacterial drug targeting WSB1. High-throughput screening of cancer drugs.

The invention provides a medicine treatment device for the oncology department and a use method thereof, and relates to the field of oncology. The medicine treatment device for the oncology department comprises a motor and two supports, wherein a treatment box is arranged on the upper sides of the two supports, the motor is fixedly connected with the right side face of the treatment box, the treatment box is fixedly connected with the two supports, two grinding wheels are arranged in the treatment box, the left side face and the right side face of each grinding wheel are each fixedly connected with four grinding plates, fine grinding plates are clamped to the exteriors of the four grinding plates located on the right side face of the right grinding wheel, a rotating shaft is inserted into the treatment box, the right grinding wheel is fixedly connected to the outside of the rotating shaft in a sleeving mode, the left grinding wheel is movably connected to the outside of the rotating shaft in a sleeving mode, and a control panel is arranged on the left side of the treatment box. According to the medicine treatment device for the oncology department, by arranging the motor, the rotating shaft, the two grinding wheels and the grinding box, the effect of fully treating medicine is achieved, and the problems that a treatment device in the prior art is not sufficient in grinding, and the time needed for sufficient grinding is long are solved.

The invention relates to the technical field of esophageal injection, and discloses a medical oncology drug delivery device and a use method thereof.The medical oncology drug delivery device comprises a deep treatment bin penetrating into the body and a control handle installed at the far end of the deep treatment bin and connected with the deep treatment bin through a pipeline; the side face of the deep treatment bin is rotationally connected with an adjusting pipe used for guiding the injection direction, and angle adjusting mechanisms used for being matched with the control handle to control rotation are installed on the two sides of the adjusting pipe. When the deep treatment bin is inserted into the oral cavity, the external control handle is matched with the adjusting wheel set to drive the angle of the adjusting pipe on the side face of the deep treatment bin to change, the whole adjusting process is simple and convenient, and the injection head is very convenient to control during inclined injection and flat injection; in addition, the influence of a convex structure on injection is avoided aiming at the injection of nipple type diseases, the multi-angle switching injection for injection treatment aiming at the center, the basal part and the edge part of a tumor is more suitable, and the operation intensity of a doctor is reduced.

The invention relates to an anti-tumor drug composition. The anti-tumor drug composition is prepared from a composition of vinorelbine and afatinib. The combination drugs are used in combination of the vinorelbine and the afatinib. Compared with a single drug, the composition has a remarkable synergistic curative effect on the treatment of a lung cancer, and an in-vitro cell experiment proves thatproliferation of NSCLC cells can be effectively inhibited through the drug combination, a scientific basis is provided for the research and development of novel oncology drugs, and meanwhile, new research ideas are provided for other drug combinations.

The present invention relates to a compound seven (6-(isoquinoline-3-amido)-6-deoxy)-β-cyclodextrin with anti-tumor activity and a preparation method thereof. Application in tumor medicine. The compound of the present invention has cytotoxicity in vitro and anti-tumor activity in vivo, and relates to the inhibitory effect on the cytotoxic activity of five tumor cell proliferations of A549, HCT-8, HeLa, SW480, and S180. The compound of the present invention has good anti-tumor activity and can It is used in the preparation of antitumor drugs, and the invention belongs to the field of biomedicine.